Literature DB >> 1386865

Early recognition of a discordant xenogeneic organ by human circulating lymphocytes.

L Inverardi1, M Samaja, R Motterlini, F Mangili, J R Bender, R Pardi.   

Abstract

Cell-mediated immune mechanisms underlying discordant xenograft rejection are poorly characterized. In our study, using a human to rat xenogeneic ex vivo model, we show that a fraction of human lymphocytes, when perfused through the coronary system of a rat heart, rapidly and specifically adheres to the vascular endothelium and infiltrates the myocardium. Lymphocyte phenotypic analysis before and after perfusion, as well as the use of purified cell subpopulations, demonstrate preferential adhesion of CD3- CD16+ NK cells. NK cell adhesion occurs via xenoreactive antibody-dependent and -independent pathways, because the selective removal of human IgG from the perfusion buffer markedly reduces but does not completely abrogate NK cell sequestration. However, T lymphocytes are retained in the xenoorgan via an antibody-independent pathway, as assessed by the lack of influence of IgG removal. Leukocyte integrins appear to play a crucial role in mediating adhesion of both lymphocyte subsets, because the pretreatment of lymphocytes with anti-CD11a, anti-CD11b, and anti-CD18 antibodies markedly reduces their retention into the xenogeneic organ. Retained human lymphocytes mediate rapid and direct damage of the xenoorgan, as demonstrated by histologic and functional alterations of the endothelium, impaired vascular resistance and in vitro lysis of rat endothelial cells by human NK cells. Taken together, these findings suggest a role for cell-mediated mechanisms in the rapid recognition and rejection of vascularized xenografts.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1386865

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  13 in total

Review 1.  Recent advances in the immunology of xenotransplantation.

Authors:  T Takahashi; S Saadi; J L Platt
Journal:  Immunol Res       Date:  1997       Impact factor: 2.829

2.  Current status of animal-to-human transplantation.

Authors:  Robert Zhong; Jeffrey L Platt
Journal:  Expert Opin Biol Ther       Date:  2005-11       Impact factor: 4.388

3.  Biochemical consequences of electrical pacing in ischemic-reperfused isolated rat hearts.

Authors:  M Samaja; S Allibardi; S L Chierchia
Journal:  Mol Cell Biochem       Date:  1999-04       Impact factor: 3.396

Review 4.  The therapeutic potential of carbon monoxide.

Authors:  Roberto Motterlini; Leo E Otterbein
Journal:  Nat Rev Drug Discov       Date:  2010-09       Impact factor: 84.694

5.  The role of antibodies in acute vascular rejection of pig-to-baboon cardiac transplants.

Authors:  S S Lin; B C Weidner; G W Byrne; L E Diamond; J H Lawson; C W Hoopes; L J Daniels; C W Daggett; W Parker; R C Harland; R D Davis; R R Bollinger; J S Logan; J L Platt
Journal:  J Clin Invest       Date:  1998-04-15       Impact factor: 14.808

6.  Xenotransplantation: Progress Along Paths Uncertain from Models to Application.

Authors:  Jeffrey L Platt; Marilia Cascalho; Jorge A Piedrahita
Journal:  ILAR J       Date:  2018-12-31

7.  Expression and function of alpha 4/beta 7 integrin on human natural killer cells.

Authors:  J J Pérez-Villar; J M Zapata; I Melero; A Postigo; E Sánchez-Madrid; M López-Botet
Journal:  Immunology       Date:  1996-09       Impact factor: 7.397

Review 8.  Natural killer cell-endothelial cell interactions in xenotransplantation.

Authors:  J R Dawson; A C Vidal; A M Malyguine
Journal:  Immunol Res       Date:  2000       Impact factor: 4.505

Review 9.  Xenotransplantation: Current Status in Preclinical Research.

Authors:  Tianyu Lu; Bochao Yang; Ruolin Wang; Chuan Qin
Journal:  Front Immunol       Date:  2020-01-23       Impact factor: 7.561

Review 10.  The Role of NK Cells in Pig-to-Human Xenotransplantation.

Authors:  Gisella Puga Yung; Mårten K J Schneider; Jörg D Seebach
Journal:  J Immunol Res       Date:  2017-12-19       Impact factor: 4.818

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.